Dexmedetomidine

Dexmedetomidine ((+) -Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].

Product Specifications

CAS Number

[113775-47-6]

Product Name Alternative

(+) -Medetomidine; (S) -Medetomidine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/dexmedetomidine.html

Purity

99.93

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

C[C@H](C1=CN=CN1)C2=CC=CC(C)=C2C

Molecular Formula

C13H16N2

Molecular Weight

200.28

Precautions

H302, H315, H319, H335

References & Citations

[1]Virtanen R, et, al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988 May 20;150 (1-2) :9-14.|[2]Gertler R, et, al. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent) . 2001 Jan;14 (1) :13-21.|[3]Sajid B, et, al. A comparison of oral dexmedetomidine and oral midazolam as premedicants in children. J Anaesthesiol Clin Pharmacol. Jan-Mar 2019;35 (1) :36-40.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

α adrenergic receptor

Citation 01

Am J Chin Med. 2025;53 (2) :501-522.|Biomed Pharmacother. 2023 Dec 31:169:115915.|Brain Res Bull. 2025 Aug 24:230:111523.|Brain Res. 2025 Jan 30:149482.|Cancer Metab. 2025 Jun 23;13 (1) :33.|Cardiovasc Drugs Ther. 2025 Feb;39 (1) :33-42.|Chem Biol Drug Des. 2025 Apr;105 (4) :e70100.|Drug Des Devel Ther. 2024 Apr 9:18:1103-1114.|Front Biosci (Landmark Ed) . 2025 Feb 20, 30 (2), 27159.|Front Biosci (Landmark Ed) . 2025 Feb 20;30 (2) :27159.|Histol Histopathol. 2025 Mar 28:18914.|Hum Exp Toxicol. 2025 Jan-Dec:44:9603271251336467.|J Neuropathol Exp Neurol. 2022 Sep 19;81 (10) :836-849.|J Toxicol Sci. 2023;48 (3) :139-148.|Kaohsiung J Med Sci. 2025 May 15:e70045.|Metab Brain Dis. 2025 Nov 5;40 (8) :306.|Mol Cell Toxicol. 2023 Jun 2.|Neurochem Res. 2025 Apr 9;50 (2) :138.|Sci Rep. 2025 Sep 29;15 (1) :33699.|University of Colorado Denver. 2024.|Eur J Neurosci. 2021 Dec;54 (11) :7775-7789.|Hum Exp Toxicol. 2021 Dec;40 (12) :2145-2155.|Nat Commun. 2023 Jul 7;14 (1) :4011.|Pharmacology. 2022;107 (1-2) :14-27.